Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2903-2912

  Emerson, David L ^a   Bendele, Ray ^a   Brown, Eric ^a   Chiang, SuMing ^a   Desjardins, John P ^a   Dihel, Larry C ^a   Gill, Stan C ^a   Hamilton, Marta ^a   LeRay, Jeremy D ^a   Moon McDermott, Lotus ^a   Moynihan, Karen ^a   Richardson, Frank C ^a   Tomkinson, Blake ^a   Luzzio, Michael J ^b,c   Baccanari, David ^b  

^a GILEAD SCIENCES   (United States)

^b GLAXOSMITHKLINE   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LURTOTECAN; TOPOTECAN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; CARBON RADIOISOTOPES; DRUG CARRIERS; FEMALE; HUMANS; KB CELLS; LIPOSOMES; MICE; MICE, NUDE; SARCOMA; TISSUE DISTRIBUTION; TOPOTECAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033911713     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., Kaufmann, S. H., and Donehower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
2. Eckardt, J. R., Burris, H. A., Rothenberg, M. L., Von Hoff, D. D., and Kuhn, J. G. Topoisomerase inhibitors: promising novel compounds. Contemp. Oncol., 47-60, 1993.
3. Rothenberg, M. L. Topoisomerase inhibitors: review and update. Ann. Oncol., 8: 837-855, 1997.
4. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufman, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
5. Kaufman, S. H. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta, 1400: 195-211, 1998.
6. Hsiang, Y-H., Hertzberg, R. P., Hecht, S. M., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
7. D'Arpa, P., and Liu, L. F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta, 989: 163-177, 1989.
8. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. Protein-link DNA strand break induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res., 49: 5016-5022, 1989.
9. Emerson, D. L., McIntyre, G., Luzzio, M. J., and Wissel, P. S. Preclinical antitumor activity of a novel water soluble camptothecin analog (GI147211C). Ann. Oncol., 5 (Suppl. 5): 185, 1994.
10. Emerson, D. L., Vuong, A., McIntyre, M. S., Croom, D. K., and Besterman, J. M. In vivo efficacy of two new water-soluble camptothecin analogues in the human cancer xenograft model. Proc. Am. Assoc. Cancer Res., 34: 119, 1993.
11. Emerson, D. L., Besterman, J. M., Brown, H. R., Evans, M. G., Leitner, P. P., Luzzio, M. J., Shaffer, J. E., Stembach, D. D., Uehling, D., and Vuong, A. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res., 55: 603-609, 1995.
12. Gerrits, C. J. H., Creemers, G. J., Schellens, J. H. M., Wissel, P., Planting, A. S., Kunka, R., Selinger, K., deBoer-Dennert, M., Marijinen, Y., Harteveld, M., and Verweij, J. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily ×5 intravenous administration. Br. J. Cancer, 73: 744-750, 1996.
13. Eckardt, S. G., Baker, S. D., Eckardt, J. R., Burke, T. G., Warner, D. L., Kuhn, J. G., Rodriguez, G., Fields, S., Thurman, A., Smith, L., Rothenberg, M. L., White, L., Wissel, P., Kunka, R., DePee, S., Littlefield, D., Burris, H. A., VonHoff, D. D., and Rowinsky, E. K. A Phase I and pharmacokinetic study of GGI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clin. Cancer Res., 4: 595-604, 1998.
14. Wissel, P., Verweij, J., Eckart, J., O'Dwyer, P., Cassidy, J., Creemers, E., Beranek, P., Littlefield, D., Depee, S., and Kunka, R. Ongoing Phase I trials of intravenous GI147211, a totally synthetic camptothecin analog, administered by the daily ×5 and 72 hr CI regimens. In: Fifth Conference on DNA Topoisomerases in Therapy, p. 32. New York; 1994.
15. Kunka, R., O'Dwyer, P., Cassidy, J., DePee, S., Littlefield, D., Selinger, K., Collis, P., Beranek, P., and Wissel, P. Pharmacokinetics (PK), and dynamics of GG211, a new topoisomerase I inhibitor, during a 72 hour continuous infusion (CI). Proc. Am. Assoc. Cancer Res., 36: 234, 1995.
16. O'Dwyer, P., Pas Arez, L., Kunka, R., DeMaria, D., Cassidy, J., Kaye, S., DePee, S., Littlefield, D., Selinger, K., Beranek, P., Graham, J., and Wissel, P. Phase I trial of the topoisomerase I inhibitor GG211 as a 72-hr infusion. Eur. J. Cancer, 31 (Suppl. 5): S193, 1995.
17. O'Dwyer, P., Cassidy, J., Kunka, R., Paz-Ares, L., Kaye, S., DePee, S., Littlefield, D., DeMaria, D., Selinger, K., Beranek, P., Collis, P., and Wissel, P. Phase I trial of GG211, a new topoisomerase inhibitor, using a 72 hr continuous infusion (CI). Proc. Am. Soc. Clin. Oncol., 14: 471, 1995.
18. Pas Arez, L., O'Dwyer, P., Cassidy, J., Kunka, R., Wissel, P., DePee, S., Littlefield, D., Adams, L., Sellinger, K., Beranek, P., Collis, P., and Kaye, S. B. Phase I clinical and pharmacokinetic study of a new topoisomerase inhibitor, GG211, given as a 72 hour continuous infusion (CI). Br. J. Cancer, 71: 10, 1995.
19. Khater, C., Twelves, C., Grochow, L., DeMaria, D., Paz-Ares, L., Littlefield, D., Pritchard, J. F., Wissel, P., Kaye, S., and O'Dwyer, P. J. Phase I trial of the topoisomerase I inhibitor GG211 as 21 day continuous infusion. Proc. Am. Soc. Clin. Oncol., 15: 483, 1996.
20. Gerrits, C. J., Schellens, J. H. M., Creemers, G. J., Wissel, P., Planting, A. S. T., Pritchard, J. F., DePee, S., de Boer-Dennert, M., Harteveld, M., and Verweij, J. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. Br. J. Cancer Res., 76: 946-951, 1997.
21. Heinrich, B., Lehnert, M., Cavalli, F., Pavlidis, N., Wanders, J., and Hanauske, A-R. Phase II trial of GI 147211 in locally advanced or metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 16: 470a, 1997.
22. Wanders, J., Oosterom, Van-AT., Gore, M., Calvert, H. A., Ten-Bokkel-Huinink, W. W., Hansen, H. H., Wissel, P., and Hanauske, A. R. A Phase II study with GI147211 in ovarian cancer. Eur. J. Cancer. 33: 118, 1997.
23. Wanders, J., Dombernowsky, P., Nielsen, D., Morant, R., Drings, P., Sessa, C., Wissel, P., and Hanauske, A. R. A Phase II study with GI147211 (GW211) in small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 17: 1823, 1998.
24. Sessa, C., Wanders, J., Dombernowsky, P., Nieisen, D., Morant, R., Drings, P., Wissel, P., and Hanauske, A. R. A Phase II study with GI147211 (GW211) in small cell lung cancer. Ann. Oncol., 9: 225, 1998.
25. Wanders, J., Ten Bokkel Huinink, W. W., Pavidis, N., Kaye, S. B., Sessa, C., Lehneri, M., Piccart, M., Pandaons, R., Wissel, P., and Hanauska, A. R. Phase II studies with GI147211 (GI) in breast (B), colorectal (C), and non-small cell lung cancer (N). Eur. J. Cancer, 33: 705, 1997.
26. Forssen, E. A, Coulter, D. M, and Proffitt, R. T., Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res., 52: 3255-3261, 1992.
27. Forssen, E. A., Male-Brune, R., Adler-Moore, J. P., Lee, M. J. A., Schmidt, P. G., Krasieva, T. B., Shimizu, S., and Tromberg, B. J. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res., 56: 2066-2075, 1996.
28. Loos, W. J., Kehrer, D., Brouwer, E., Verweij, J., de Bruijn, P., Hamilton, M., Gill, S. C., Nooter, K., Stoter, G., and Sparreboom, A., Liposomal lurtotecan (NX 211). Determination of total drug levels in human plasma and urine by reversed-phase HPLC. J. Chromatogr., 738: 155-163, 1999.
29. Mayer, L. D., Masin, D., Nayar, R., Boman, N. L., and Bally, M. B., Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumors. Br. J. Cancer, 71: 482-488, 1995.
30. Lim, H. J., Masin, D., Madden, T. D., and Bally, M. B. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J. Pharmacol. Exp. Ther., 281: 566-573, 1997.
31. Subramanian, D., and Muller, M. T. Liposomal encapsulation increases the activity of the topoisomerase inhibitor topotecan. Oncol. Res., 7: 461-469, 1995.
32. Gabizon, A., Goren, D., Fuks, Z., Meshorer, A., and Barenholz, Y. Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br. J. Cancer, 51: 681-689, 1985.
33. Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J. A., Liebman, H. A., Forssen, E., Ross, M. E., and Levine, A. M. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol., 13: 996-1003, 1995.
34. Hamilton, M., Meyer, D. J., Desjardins, J. P., Tomkinson, B. E., Hooson, K. L., Emerson, D. L., Bendele, A. M., Dihel, L. C., Moon-McDermott, L., LeRay, J. D., Brown, E., Richardson, F. C., Gill, S. C., Moynihan, K. L., Chiang, S. M., and Bendele, R. A. Pharmacokinetics, distribution, and toxicology of NX 211 (liposomal lurtotecan) in mice and rats. Proc. Am. Soc. Clin. Oncol., 18: 177a, 1999.
35. Colbern, G. T., Dykes, D. J., Engbers, C., Musterer, R., Hiller, A., Pegg, E., Saville, R., Weng, S., Luzzio, M., Uster, P., Amantea, M., and Working, P. K. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer Res., 4: 3077-3082, 1998.
36. Parr, M. J., Masin, D., Cullis, P. R., and Bally, M. B. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J. Pharmacol. Exp. Ther., 280: 1319-1327, 1997.
37. Gabizon, A., and Papahadjopoulos, D. Liposome formulations with prolonged circulation and time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA, 85: 6949-6953, 1988.
38. Gabizon, A., Shiota, R., and Papahadjiopoulos, D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst., 81: 1484-1488, 1989.
39. Dvorak, H. F., Nagy, J. A., Dvorak, J. T., and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133: 95-109, 1988.
40. Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., and Jain, R. K. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res., 54: 3352-3356, 1994.
41. Hochster, H., Liebes, L., Speyer, J., Taubes, B., Oratz, R., Wern, E. J., Chahoua, A., Raphael, B., Vinci, R. E., and Blim, R. H. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol., 12: 553-559, 1994.